Pathophysiology and epidemiology of peripartum cardiomyopathy

Nature Reviews Cardiology

Volumn 11, Issue 6, 2014, Pages 364-370

  Hilfiker Kleiner, Denise ^a   Sliwa, Karen ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; MICRORNA 146A; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLACTIN; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; VASCULOTROPIN;

CARDIOVASCULAR MORTALITY; CONGESTIVE CARDIOMYOPATHY; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; ETHNIC GROUP; FAMILIAL DISEASE; GENETIC PREDISPOSITION; HEREDITY; HUMAN; INCIDENCE; MORBIDITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPARTUM CARDIOMYOPATHY; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS; UPREGULATION;

CARDIOMYOPATHIES; FEMALE; HUMANS; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS;

EID: 84901480496     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.37     Document Type: Review

References (67)

1. Pearson, G. D. et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283, 1183-1188 (2000). (Pubitemid 30126607)
2. Selle, T., Renger, I., Labidi, S., Bultmann, I. & Hilfiker-Kleiner, D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol. 5, 175-189 (2009).
3. Sliwa, K., Fett, J. & Elkayam, U. Peripartum cardiomyopathy. Lancet 368, 687-693 (2006). (Pubitemid 44223695)
4. Sliwa, K. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Eur. Heart J. 12, 767-778 (2010).
5. Demakis, J. G. & Rahimtoola, S. H. Peripartum cardiomyopathy. Circulation 44, 964-968 (1971).
6. Elkayam, U. et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111, 2050-2055 (2005). (Pubitemid 40577899)
7. Haghikia, A. et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 108, 366 (2013).
8. Goland, S. et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J. Card. Fail. 15, 645-650 (2009).
9. Sliwa, K. et al. Peripartum cardiomyopathy: Inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 27, 441-446 (2006). (Pubitemid 43209169)
10. Halkein, J. et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Invest. 123, 2143-2154 (2013).
11. Hilfiker-Kleiner, D. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600 (2007). (Pubitemid 46206082)
12. Patten, I. S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333-338 (2012).
13. Forster, O. et al. Reversal of IFN, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur. J. Heart Fail. 10, 861-868 (2008).
14. Ricke-Hoch, M. et al. Opposing roles of Akt and STAT3 in protection of the maternal heart from peripartum stress. Cardiovasc. Res. 101, 587-596 (2014).
15. Kamiya, C. A. et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders: results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ. J. 75, 1975-1981 (2011).
16. Brar, S. S. et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am. J. Cardiol. 100, 302-304 (2007). (Pubitemid 47041992)
17. Fett, J. D. Peripartum cardiomyopathy: Insights from Haiti regarding a disease of unknown etiology. Minn. Med. 85, 46-48 (2002).
18. Fett, J. D., Christie, L. G., Carraway, R. D. & Murphy, J. G. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin. Proc. 80, 1602-1606 (2005). (Pubitemid 41747062)
19. Kuklina, E. V. & Callaghan, W. M. Cardiomyopathy and other myocardial disorders among hospitalizations for pregnancy in the United States: 2004-2006. Obstet. Gynecol. 115, 93-100 (2010).
20. Fett, J. D. et al. Unrecognized peripartum cardiomyopathy in Haitian women. Int. J. Gynaecol. Obstet. 90, 161-166 (2005). (Pubitemid 40984022)
21. Desai, D., Moodley, J. & Naidoo, D. Peripartum cardiomyopathy: Experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop. Doct. 25, 118-123 (1995).
22. Chapa, J. B. et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet. Gynecol. 105, 1303-1308 (2005). (Pubitemid 40734261)
23. Gentry, M. B. et al. African-American women have a higher risk for developing peripartum cardiomyopathy. J. Am. Coll. Cardiol. 55, 654-659 (2010).
24. Modi, K. A., Illum, S., Jariatul, K., Caldito, G. & Reddy, P. C. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am. J. Obstet. Gynecol. 201, 171. e1-e5 (2009).
25. Goland, S., Modi, K., Hatamizadeh, P. & Elkayam, U. Differences in clinical profile of African-American women with peripartum cardiopmyopathy in the United States. J. Card. Fail. 19, 214-218 (2013).
26. Blauwet, L. A. et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 99, 308-313 (2013).
27. Mielniczuk, L. M. et al. Frequency of peripartum cardiomyopathy. Am. J. Cardiol. 97, 1765-1768 (2006). (Pubitemid 43817868)
28. European Society of Cardiology. PeriPartum CardioMyopathy (PPCM) Registry [online], http://www.escardio. org/guidelines-surveys/eorp/surveys/ppcm/Pages/ peripartum-cardiomyopathy. aspx (2014).
29. Elkayam, U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J. Am. Coll. Cardiol. 58, 659-670 (2011).
30. Safirstein, J. G. et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int. J. Cardiol. 154, 27-31 (2012).
31. Sliwa, K. et al. EURObservational Research Programme: A worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur. J. Heart Fail. http://dx. doi. org/10. 1002/ejhf. 68.
32. Pearl, W. Familial occurrence of peripartum cardiomyopathy. Am. Heart J. 129, 421-422 (1995).
33. Pierce, J. A., Price, B. O. & Joyce, J. W. Familial occurrence of postpartal heart failure. Arch. Intern. Med. 111, 651-655 (1963).
34. Meyer, G. P. et al. Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. J. Med. Case Reports 4, 80 (2010).
35. Fett, J. D., Sundstrom, B. J., Etta King, M. & Ansari, A. A. Mother-daughter peripartum cardiomyopathy. Int. J. Cardiol. 86, 331-332 (2002).
36. van Spaendonck-Zwarts, K. et al. Peripartum cardiomyopathy as part of familial dilated cardiomyopathy. Circulation 121, 2169-2175 (2010).
37. Morales, A. et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 121, 2176-2182 (2010).
38. van Spaendonck-Zwarts, K. Y. et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur. Heart J. http://dx. doi. org/10. 1093/eurheartj/ehu050.
39. Bahl, A., Swamy, A., Sharma, Y. & Kumar, N. Isolated noncompaction of left ventricle presenting as peripartum cardiomyopathy. Int. J. Cardiol. 109, 422-423 (2006).
40. Lea, B., Bailey, A. L., Wiisanen, M. E., Attili, A. & Rajagopalan, N. Left ventricular noncompaction presenting as peripartum cardiomyopathy. Int. J. Cardiol. 154, e65-e66 (2012).
41. Rehfeldt, K. H., Pulido, J. N., Mauermann, W. J. & Click, R. L. Left ventricular hypertrabeculation/noncompaction in a patient with peripartum cardiomyopathy. Int. J. Cardiol. 139, e18-e20 (2010).
42. Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E. & Sliwa, K. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr. Heart Fail. Rep. 9, 174-182 (2012).
43. Toescu, V., Nuttall, S. L., Martin, U., Kendall, M. J. & Dunne, F. Oxidative stress and normal pregnancy. Clin. Endocrinol. (Oxf.) 57, 609-613 (2002). (Pubitemid 35316977)
44. Lkhider, M., Castino, R., Bouguyon, E., Isidoro, C. & Ollivier-Bousquet, M. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. J. Cell Sci. 117, 5155-5164 (2004). (Pubitemid 39517530)
45. Ferrara, N., Clapp, C. & Weiner, R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129, 896-900 (1991).
46. Piwnica, D. et al. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol. Endocrinol. 18, 2522-2542 (2004). (Pubitemid 39335986)
47. Macotela, Y. et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J. Cell Sci. 119, 1790-1800 (2006). (Pubitemid 43811005)
48. Tabruyn, S. P., Nguyen, N. Q., Cornet, A. M., Martial, J. A. & Struman, I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol. Endocrinol. 19, 1932-1942 (2005). (Pubitemid 41007903)
49. D'Angelo, G. et al. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13, 692-704 (1999). (Pubitemid 30645323)
50. Tabruyn, S. P. et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-B. Mol. Endocrinol. 17, 1815-1823 (2003). (Pubitemid 37072297)
51. Lee, S. H., Kunz, J., Lin, S. H. & Yu-Lee, L. Y. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res. 67, 11045-11053 (2007). (Pubitemid 350145935)
52. Gonzalez, C. et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145, 5714-5722 (2004). (Pubitemid 39564613)
53. Gonzalez, C. et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab. Invest. 87, 1009-1017 (2007). (Pubitemid 47429188)
54. Nguyen, N. Q. et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol. Ther. 15, 2094-2100 (2007).
55. Habedank, D. et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur. J. Heart Fail. 10, 1149-1151 (2008).
56. Hilfiker-Kleiner, D. et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J. Am. Coll. Cardiol. 50, 2354-2355 (2007). (Pubitemid 350192108)
57. Sliwa, K. et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study. Circulation 121, 1465-1473 (2010).
58. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials. gov/ct2/show/NCT00998556 (2012).
59. Bello, N., Rendon, I. S. & Arany, Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 62, 1715-1723 (2013).
60. Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911-919 (2012).
61. Shahul, S. et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: A 2D speckle-tracking imaging study. Circ. Cardiovasc. Imaging 5, 734-739 (2012).
62. Powe, C. E., Levine, R. J. & Karumanchi, S. A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123, 2856-2869 (2011).
63. Fett, J. D. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol. 9, 809-816 (2013).
64. Elkayam, U. et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N. Engl. J. Med. 344, 1567-1571 (2001). (Pubitemid 32479908)
65. Chung, E., Yeung, F. & Leinwand, L. A. Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. J. Appl. Physiol. (1985) 112, 1564-1575 (2012).
66. Eghbali, M. et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ. Res. 96, 1208-1216 (2005). (Pubitemid 40827697)
67. Walenta, K. et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 33, 1469-1479 (2012).